Form 4: Cidara CEO Sells Shares in Merck Acquisition

Jeffrey Stein, President & CEO of Cidara Therapeutics, Inc., disposed of all his common stock and derivative securities following the company's acquisition by Merck Sharp & Dohme LLC.

Summary

• Cidara Therapeutics, Inc. was acquired by Merck Sharp & Dohme LLC through its subsidiary, Caymus Purchaser, Inc., with the tender offer completed and merger effective on January 7, 2026.
• Common Shares were acquired for $221.50 per share in cash, and Series A Convertible Voting Preferred Stock for $15,505.00 per share in cash.
• Jeffrey Stein, as Director, President & CEO, disposed of 5,763 direct common shares, 2,379 indirect common shares held by his son, and 67,498 indirect common shares held by a trust.
• All outstanding employee stock options held by Mr. Stein became fully vested and exercisable, then cancelled and converted into cash based on the difference between the merger consideration ($221.50) and the option's exercise price.
• The exercise prices and number of securities for derivative holdings were adjusted to reflect a 1-for-20 reverse stock split effected on April 24, 2024.
• Following these transactions, Jeffrey Stein beneficially owns 0 common shares and 0 derivative securities of Cidara Therapeutics, Inc.

Sentiment

Score: 8

Explanation: The sentiment is highly positive for shareholders due to the successful completion of an acquisition at a significant cash premium, providing a clear and lucrative exit.

Positives

• Shareholders received a significant cash consideration for their shares, with Common Shares valued at $221.50 each and Series A Shares at $15,505.00 each.
• The acquisition provides a clear exit strategy and liquidity for Cidara Therapeutics shareholders.

Negatives

• Cidara Therapeutics, Inc. ceases to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Merck.
• The reporting person, Jeffrey Stein, no longer holds any beneficial ownership in the company.

Future Outlook

Cidara Therapeutics, Inc. is now a wholly-owned subsidiary of Merck Sharp & Dohme LLC, and its independent operations and public market outlook have ceased.

Industry Context

This acquisition reflects ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies often acquire smaller biotech firms to expand their pipelines and intellectual property portfolios.

Related Party Transactions

• Jeffrey Stein's indirect beneficial ownership included shares held by his son and by a trust, which were also disposed of as part of the merger.

Stakeholder Impact

• Shareholders: Received cash consideration for their shares, providing liquidity and a return on investment.
• Employees (including management): Cidara Therapeutics is now part of Merck, which will likely lead to integration and potential changes in roles or reporting structures.
• Company: Cidara Therapeutics ceases to exist as an independent public entity, becoming a subsidiary of Merck.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Merck, Acquisition, Merger, Tender Offer, Form 4, Insider Transaction, Stock Options, Biotechnology, Pharmaceuticals